MCID: LNG064
MIFTS: 62

Lung Cancer Susceptibility 3 malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

Aliases & Descriptions for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 52 12 68
Adenocarcinoma of Lung 11 27 39 68
Lung Adenocarcinoma 35 11 48 13
 
Non-Small Cell Adenocarcinoma 68
Nonsmall Cell Adenocarcinoma 11
Adenocarcinoma Lung 50

Classifications:



External Ids:

OMIM52 612571
Disease Ontology11 DOID:3910
SNOMED-CT62 254626006
MeSH39 C538231

Summaries for Lung Cancer Susceptibility 3

About this section
NIH Rare Diseases:48 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. it is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. early lung cancers may not be associated with any signs and symptoms. as the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. the underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and hiv infection. treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. it may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting. last updated: 2/10/2016

MalaCards based summary: Lung Cancer Susceptibility 3, also known as adenocarcinoma of lung, is related to interstitial lung disease and marginal zone b-cell lymphoma. An important gene associated with Lung Cancer Susceptibility 3 is LNCR3 (Lung Cancer Susceptibility 3), and among its related pathways are EGFR Transactivation by Gastrin and Mitophagy - animal. Affiliated tissues include lung, breast and endothelial, and related mouse phenotypes are Decreased viability with paclitaxel and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance.

Disease Ontology:11 A non-small cell lung carcinoma that derives from epithelial cells of glandular origin.

Wikipedia:71 Lung cancer susceptibility 3 is a protein that in humans is encoded by the LNCR3 gene. more...

Description from OMIM:52 612571

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 5 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 2

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 318)
idRelated DiseaseScoreTop Affiliating Genes
1interstitial lung disease30.0EGFR, TP53, VEGFA
2marginal zone b-cell lymphoma29.6EGFR, MMP2, TP53, VEGFA
3peritoneal mesothelioma29.6CDH1, HRAS, KRAS, NKX2-1, TP53
4colorectal cancer28.8CASP3, CDH1, CEACAM5, EGFR, ERBB2, HRAS
5bronchogenic lung adenocarcinoma11.8
6adenocarcinoma11.1
7tumor predisposition syndrome10.9
8lung papillary adenocarcinoma10.8
9severe pre-eclampsia10.4EGFR, HRAS, KRAS
10ureter adenocarcinoma10.4EGFR, KRAS, NKX2-1
11bile duct disease10.4EGFR, HRAS, KRAS
12bone deterioration disease10.4KRAS, NKX2-1, TP53
13ovarian embryonal carcinoma10.4EGFR, NKX2-1, TP53
14pineal region mature teratoma10.4EGFR, ERBB2
15breast pericanalicular fibroadenoma10.4KRT20, NKX2-1, TP53
16ossifying fibromyxoid tumor10.4HRAS, KRAS, TP53
17pelvic inflammatory disease10.4HRAS, KRAS, KRT20
18malignant skin fibrous histiocytoma10.4CEACAM5, HRAS, KRAS
19reactive arthritis10.4EGFR, ERBB2, TP53
20combined t cell and b cell immunodeficiency10.4CDH1, EGFR, ERBB2
21ovarian cystadenocarcinoma10.4EGFR, ERBB2, VEGFA
22aicardi-goutieres syndrome10.4HRAS, KRAS, TP53
23giant cell tumor10.4KRAS, KRT20, TP53
24kidney clear cell sarcoma10.4EGFR, HRAS, KRAS, NKX2-1
25linitis plastica10.4CDH1, TP53
26exudative glomerulonephritis10.4EGFR, KRAS, NKX2-1, TP53
27spastic paraplegia 110.4EGFR, TP53, VEGFA
28skin sarcoma10.4CEACAM5, EGFR, ERBB2
29pancreatic agenesis10.4EGFR, KRT20, NKX2-1
30nervous system hibernoma10.4EGFR, ERBB2, KRT7
31wolffian adnexal neoplasm10.3EGFR, TP53
32myxedema10.3EGFR, HRAS, KRAS, TP53
33striated muscle rhabdoid tumor10.3HRAS, KRAS, MMP2
34spongiotic dermatitis10.3EGFR, ERBB2, HRAS, KRAS
35vascular hemostatic disease10.3EGFR, ERBB2, HRAS, KRAS
36retroperitoneal neuroblastoma10.3KRAS, NAPSA, TP53
37spasmodic dysphonia10.3KRT20, KRT7, NKX2-1
38nemaline myopathy 8, autosomal recessive10.3CDH1, ERBB2, KRAS
39spastic diplegia infantile type10.3EGFR, ERBB2, KRAS
40peritoneal benign neoplasm10.3KRT20, KRT7, STK11
41dystonia10.3KRT20, KRT7, STK11
42anal canal paget's disease10.3KRT20, KRT7, STK11
43pancreatic cystadenoma10.3EGFR, KRAS, NAPSA, TP53
44sclerosing hemangioma10.3CDH1, EGFR, ERBB2
45arthus reaction10.3ERBB2, HRAS, KRAS, TP53
46retinal disease10.3CDH1, EGFR, ERBB2
47cervical serous adenocarcinoma10.3CEACAM5, HRAS, KRAS
48anus adenocarcinoma10.3EGFR, ERBB2, KRT20
49breast mucinous cystadenocarcinoma10.3CEACAM5, HRAS, KRAS
50bilateral hypoactive labyrinth10.3HRAS, KRAS, KRT7

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to lung cancer susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

About this section


Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00293-A10.4CASP3, EGFR, ERBB2
2GR00210-A10.1EGFR, ERBB2, HRAS, STK11, VEGFA

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

41 (show all 18)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.5CASP3, EGFR, ERBB2, HRAS, KRAS, MMP2
2MP:00053899.4CASP3, CDH1, EGFR, ERBB2, KRAS, NKX2-1
3MP:00053679.4CASP3, EGFR, HRAS, KRAS, KRT7, STK11
4MP:00053699.3CASP3, EGFR, ERBB2, KRAS, MMP2, STK11
5MP:00053909.3CASP3, EGFR, ERBB2, HRAS, KRAS, MMP2
6MP:00053709.2EGFR, KRAS, OGG1, RASSF1, STK11, TP53
7MP:00030129.0CASP3, CDH1, EGFR, HRAS, KRAS, NKX2-1
8MP:00107719.0CASP3, CDH1, EGFR, ERBB2, HRAS, KRAS
9MP:00053889.0CASP3, EGFR, ERBB2, HRAS, KRAS, MMP2
10MP:00053818.9CASP3, CDH1, EGFR, ERBB2, KRAS, NKX2-1
11MP:00020068.9CDH1, EGFR, ERBB2, HRAS, KRAS, MMP2
12MP:00053798.8CASP3, CDH1, EGFR, ERBB2, HRAS, KRAS
13MP:00053858.6CASP3, CDH1, EGFR, ERBB2, HRAS, KRAS
14MP:00053848.6CASP3, CDH1, EGFR, ERBB2, KRAS, KRT7
15MP:00107688.5CASP3, CDH1, EGFR, ERBB2, HRAS, KRAS
16MP:00028738.4CDH1, EGFR, ERBB2, HRAS, KRAS, MMP2
17MP:00036318.3CASP3, EGFR, ERBB2, HRAS, KRAS, MMP2
18MP:00053768.3CASP3, CDH1, EGFR, ERBB2, HRAS, KRAS

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Gilotrif16 44 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
FDA Label: Gilotrif
Disease/s that Drug Treats:metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:16 GILOTRIF is a kinase inhibitor indicated for the first-line treatment ofpatients with metastatic non-small cell lung cancer (NSCLC) whose tumorshave epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21(L858R) substitution mutations as detected by an FDA-approved test (1)Limitation of Use: Safety and efficacy of GILOTRIF have not beenestablished in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:14 1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2;3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:16 
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) andirreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtypeEGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, inpatients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors eitheroverexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 459)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 1, Phase 2370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
2
CisplatinapprovedPhase 4, Phase 2, Phase 3, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3
Pemetrexedapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1636150399-23-8, 137281-23-3446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
 
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
4
Paclitaxelapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
5
Sunitinibapproved, investigationalPhase 4, Phase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
6
GemcitabineapprovedPhase 4, Phase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
7
MentholapprovedPhase 426062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
8
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1361184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
9
EverolimusapprovedPhase 4, Phase 3, Phase 1, Phase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
10
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
11
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
12
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
13
RibavirinapprovedPhase 4100336791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
14
Peginterferon alfa-2aapproved, investigationalPhase 4565198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
 
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Pegylated interferon alfa-2a
Pegylated interferon alpha2a
15
Midazolamapproved, illicitPhase 4, Phase 172359467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
16
leucovorinapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
17
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
18
Caffeineapproved, NutraceuticalPhase 439658-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
19
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 2, Phase 3, Phase 11967114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
20Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 14337
21interferonsPhase 4, Phase 2, Phase 12175
22AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 112054
23Folic Acid AntagonistsPhase 4, Phase 3, Phase 2, Phase 12257
24Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14962
25Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 19967
26Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 17361
27Albumin-Bound PaclitaxelPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12864
28Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 111226
29Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 13689
30MitogensPhase 4, Phase 3, Phase 2, Phase 11617
31pancreatic polypeptidePhase 4, Phase 2, Phase 3, Phase 120
32
Erlotinib HydrochloridePhase 4, Phase 3, Phase 2, Phase 1810183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
33Angiogenesis Modulating AgentsPhase 4, Phase 2, Phase 3, Phase 14185
34Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
35Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 113086
36Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
37Angiogenesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 14257
38Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15602
39Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15657
40Antifungal AgentsPhase 4, Phase 3, Phase 1, Phase 23696
41Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 122062
42Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 123689
43Nicotinic AgonistsPhase 4945
44Cholinergic AgentsPhase 43992
45Autonomic AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 110150
46Anti-Anxiety AgentsPhase 4, Phase 11885
47Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 113403
48GABA AgentsPhase 4, Phase 11684
49GABA ModulatorsPhase 4, Phase 1904
50Anesthetics, IntravenousPhase 4, Phase 3, Phase 12538

Interventional clinical trials:

(show top 50)    (show all 844)
idNameStatusNCT IDPhase
1Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal CancerUnknown statusNCT00628784Phase 4
2Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsUnknown statusNCT00454376Phase 4
3A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4
4RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4
5Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
6Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular CarcinomaCompletedNCT00630084Phase 4
7Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT01595009Phase 4
8Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
9Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung AdenocarcinomaRecruitingNCT02804646Phase 4
10Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaRecruitingNCT02103257Phase 4
11Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaRecruitingNCT01665417Phase 4
12Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerRecruitingNCT02031601Phase 4
13Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene MutationActive, not recruitingNCT02283424Phase 4
14Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCActive, not recruitingNCT02194556Phase 4
15Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyActive, not recruitingNCT02151149Phase 4
16Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaNot yet recruitingNCT02399566Phase 4
17Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT00536107Phase 4
18Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyUnknown statusNCT01066195Phase 3
19Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung CancerUnknown statusNCT00955695Phase 3
20Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer PatientsUnknown statusNCT01802021Phase 2, Phase 3
21Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)Unknown statusNCT01429649Phase 3
22Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsUnknown statusNCT00227617Phase 2, Phase 3
23Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial PneumoniaUnknown statusNCT01796717Phase 2, Phase 3
24First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never SmokerCompletedNCT00455936Phase 3
25Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinCompletedNCT00966914Phase 3
26BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationCompletedNCT00949650Phase 3
27ADAM-Afatinib Diarrhea Assessment and ManagementCompletedNCT01814553Phase 3
28Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung CancerCompletedNCT01404260Phase 3
29Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During SurgeryCompletedNCT00003387Phase 3
30Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00005838Phase 3
31Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung CancerCompletedNCT00002852Phase 3
32Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00020709Phase 3
33Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung CancerCompletedNCT00021060Phase 2, Phase 3
34Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung CancerCompletedNCT00002550Phase 3
35Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung CancerCompletedNCT00003831Phase 3
36Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically RemovedCompletedNCT00003235Phase 3
37Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryCompletedNCT00049543Phase 3
38Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00079287Phase 3
39Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT00002623Phase 3
40Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung CancerCompletedNCT00028938Phase 3
41Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedNCT00006484Phase 3
42Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by SurgeryCompletedNCT00003901Phase 3
43Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerCompletedNCT00002823Phase 3
44Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung CancerCompletedNCT00003685Phase 3
45Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT00003117Phase 3
46An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing RadiationCompletedNCT00132704Phase 3
47ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresCompletedNCT00404924Phase 3
48Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for ApoptosisCompletedNCT00243685Phase 2, Phase 3
49Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue SarcomaCompletedNCT00002764Phase 3
50Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00056446Phase 3

Search NIH Clinical Center for Lung Cancer Susceptibility 3


Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Genetic tests related to Lung Cancer Susceptibility 3:

id Genetic test Affiliating Genes
1 Adenocarcinoma of Lung27
2 Lung Adenocarcinoma27

Anatomical Context for Lung Cancer Susceptibility 3

About this section

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

36
Lung, Breast, Endothelial, Testes, Adipocyte

Publications for Lung Cancer Susceptibility 3

About this section

Variations for Lung Cancer Susceptibility 3

About this section

Clinvar genetic disease variations for Lung Cancer Susceptibility 3:

5 (show all 75)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.742C> T (p.Arg248Trp)SNVPathogenic/ Likely pathogenicrs121912651GRCh37Chr 17, 7577539: 7577539
2TP53NM_ 000546.5(TP53): c.733G> T (p.Gly245Cys)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
3TP53NM_ 000546.5(TP53): c.725G> A (p.Cys242Tyr)SNVPathogenic/ Likely pathogenicrs121912655GRCh37Chr 17, 7577556: 7577556
4TP53NM_ 000546.5(TP53): c.734G> A (p.Gly245Asp)SNVPathogenic/ Likely pathogenicrs121912656GRCh37Chr 17, 7577547: 7577547
5TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
6TP53NM_ 000546.5(TP53): c.722C> T (p.Ser241Phe)SNVPathogenic/ Likely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
7TP53NM_ 000546.5(TP53): c.733G> A (p.Gly245Ser)SNVPathogenic/ Likely pathogenicrs28934575GRCh37Chr 17, 7577548: 7577548
8TP53NM_ 000546.5(TP53): c.818G> A (p.Arg273His)SNVPathogenic/ Likely pathogenicrs28934576GRCh37Chr 17, 7577120: 7577120
9TP53NM_ 000546.5(TP53): c.451C> A (p.Pro151Thr)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
10TP53NM_ 000546.5(TP53): c.451C> T (p.Pro151Ser)SNVPathogenic/ Likely pathogenicrs28934874GRCh37Chr 17, 7578479: 7578479
11HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
12HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
13HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
14HRASNM_ 005343.3(HRAS): c.436G> A (p.Ala146Thr)SNVPathogenic/ Likely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
15HRASNM_ 005343.3(HRAS): c.437C> T (p.Ala146Val)SNVPathogenic/ Likely pathogenicrs121917759GRCh37Chr 11, 533466: 533466
16HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
17TP53NM_ 000546.5(TP53): c.488A> G (p.Tyr163Cys)SNVPathogenic/ Likely pathogenicrs148924904GRCh37Chr 17, 7578442: 7578442
18TP53NM_ 000546.5(TP53): c.535C> T (p.His179Tyr)SNVPathogenic/ Likely pathogenicrs587780070GRCh37Chr 17, 7578395: 7578395
19TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
20TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
21PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
22PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
23PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
24PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
25NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
26RAF1NM_ 002880.3(RAF1): c.770C> T (p.Ser257Leu)SNVPathogenic/ Likely pathogenicrs80338796GRCh37Chr 3, 12645699: 12645699
27BRAFNM_ 004333.4(BRAF): c.1801A> G (p.Lys601Glu)SNVPathogenic/ Likely pathogenicrs121913364GRCh37Chr 7, 140453134: 140453134
28BRAFNM_ 004333.4(BRAF): c.1405G> C (p.Gly469Arg)SNVPathogenic/ Likely pathogenicrs121913357GRCh37Chr 7, 140481403: 140481403
29BRAFNM_ 004333.4(BRAF): c.1406G> C (p.Gly469Ala)SNVPathogenic/ Likely pathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
30BRAFNM_ 004333.4(BRAF): c.1781A> G (p.Asp594Gly)SNVPathogenic/ Likely pathogenicrs121913338GRCh37Chr 7, 140453154: 140453154
31BRAFNM_ 004333.4(BRAF): c.1406G> A (p.Gly469Glu)SNVPathogenic/ Likely pathogenicrs121913355GRCh37Chr 7, 140481402: 140481402
32AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
33TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
34TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
35TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
36IDH1NM_ 001282386.1(IDH1): c.395G> A (p.Arg132His)SNVPathogenic/ Likely pathogenicrs121913500GRCh38Chr 2, 208248388: 208248388
37PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
38CTNNB1NM_ 001904.3(CTNNB1): c.98C> A (p.Ser33Tyr)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
39CTNNB1NM_ 001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
40CTNNB1NM_ 001904.3(CTNNB1): c.98C> T (p.Ser33Phe)SNVPathogenic/ Likely pathogenicrs121913400GRCh37Chr 3, 41266101: 41266101
41CTNNB1NM_ 001904.3(CTNNB1): c.110C> T (p.Ser37Phe)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
42HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
43TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
44TP53NM_ 000546.5(TP53): c.856G> A (p.Glu286Lys)SNVPathogenic/ Likely pathogenicrs786201059GRCh37Chr 17, 7577082: 7577082
45TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
46TP53NM_ 000546.5(TP53): c.584T> C (p.Ile195Thr)SNVPathogenic/ Likely pathogenicrs760043106GRCh38Chr 17, 7674947: 7674947
47PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
48TP53NM_ 000546.5(TP53): c.833C> T (p.Pro278Leu)SNVPathogenic/ Likely pathogenicrs876659802GRCh37Chr 17, 7577105: 7577105
49SMAD4NM_ 005359.5(SMAD4): c.1081C> G (p.Arg361Gly)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
50SMAD4NM_ 005359.5(SMAD4): c.1082G> A (p.Arg361His)SNVPathogenic/ Likely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
51NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
52PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
53HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
54NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
55NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
56DNMT3ANM_ 175629.2(DNMT3A): c.2645G> C (p.Arg882Pro)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
57DNMT3ANM_ 175629.2(DNMT3A): c.2645G> A (p.Arg882His)SNVPathogenic/ Likely pathogenicrs147001633GRCh37Chr 2, 25457242: 25457242
58DNMT3ANM_ 175629.2(DNMT3A): c.2644C> T (p.Arg882Cys)SNVPathogenic/ Likely pathogenicrs377577594GRCh37Chr 2, 25457243: 25457243
59IDH1NM_ 005896.3(IDH1): c.395G> T (p.Arg132Leu)SNVPathogenic/ Likely pathogenicrs121913500GRCh37Chr 2, 209113112: 209113112
60IDH1NM_ 001282387.1(IDH1): c.394C> T (p.Arg132Cys)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
61IDH1NM_ 001282387.1(IDH1): c.394C> G (p.Arg132Gly)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
62IDH1NM_ 001282387.1(IDH1): c.394C> A (p.Arg132Ser)SNVPathogenic/ Likely pathogenicrs121913499GRCh37Chr 2, 209113113: 209113113
63CTNNB1NM_ 001904.3(CTNNB1): c.110C> A (p.Ser37Tyr)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
64PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
65BRAFNM_ 004333.4(BRAF): c.1780G> C (p.Asp594His)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
66TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
67TP53NM_ 000546.5(TP53): c.523C> G (p.Arg175Gly)SNVPathogenic/ Likely pathogenicrs138729528GRCh37Chr 17, 7578407: 7578407
68PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
69BRAFNM_ 004333.4(BRAF): c.1787G> T (p.Gly596Val)SNVPathogenic/ Likely pathogenicrs397507483GRCh37Chr 7, 140453148: 140453148
70BRAFNM_ 004333.4(BRAF): c.1780G> A (p.Asp594Asn)SNVPathogenic/ Likely pathogenicrs397516896GRCh37Chr 7, 140453155: 140453155
71BRAFNM_ 004333.4(BRAF): c.1802A> C (p.Lys601Thr)SNVPathogenic/ Likely pathogenicrs397507484GRCh37Chr 7, 140453133: 140453133
72KRASNM_ 033360.3(KRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs17851045GRCh37Chr 12, 25380275: 25380275
73NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
74SMAD4NM_ 005359.5(SMAD4): c.1081C> T (p.Arg361Cys)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
75SMAD4NM_ 005359.5(SMAD4): c.1157G> A (p.Gly386Asp)SNVPathogenic/ Likely pathogenicrs121912580GRCh37Chr 18, 48593406: 48593406

Cosmic variations for Lung Cancer Susceptibility 3:

8 (show top 50)    (show all 1512)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM6224EGFRlung,NS,carcinoma,adenocarcinomac.2573T>Gp.L858R16
2COSM10750TP53lung,NS,carcinoma,adenocarcinomac.490A>Tp.K164*16
3COSM520KRASlung,NS,carcinoma,adenocarcinomac.35G>Tp.G12V16
4COSM516KRASlung,NS,carcinoma,adenocarcinomac.34G>Tp.G12C16
5COSM5062PTENlung,NS,carcinoma,adenocarcinomac.1123G>Ap.D375N16
6COSM48362ERBB4lung,NS,carcinoma,adenocarcinomac.2791G>Tp.D931Y16
7COSM48997NF1lung,NS,carcinoma,adenocarcinomac.3975-2A>Gp.?16
8COSM521KRASlung,NS,carcinoma,adenocarcinomac.35G>Ap.G12D16
9COSM522KRASlung,NS,carcinoma,adenocarcinomac.35G>Cp.G12A16
10COSM48483LMTK2lung,NS,carcinoma,adenocarcinomac.484G>Tp.V162L16
11COSM6240EGFRlung,NS,carcinoma,adenocarcinomac.2369C>Tp.T790M16
12COSM10731TP53lung,NS,carcinoma,adenocarcinomac.707A>Gp.Y236C16
13COSM94696MERTKlung,NS,carcinoma,adenocarcinomac.2152A>Tp.N718Y16
14COSM94486IGFBP1lung,NS,carcinoma,adenocarcinomac.455G>Cp.W152S16
15COSM527KRASlung,NS,carcinoma,adenocarcinomac.37G>Tp.G13C16
16COSM93949ADGRB3lung,NS,carcinoma,adenocarcinomac.4211G>Tp.G1404V16
17COSM10905TP53lung,NS,carcinoma,adenocarcinomac.451C>Tp.P151S16
18COSM93855ADAMTS18lung,NS,carcinoma,adenocarcinomac.1058G>Ap.G353E16
19COSM532KRASlung,NS,carcinoma,adenocarcinomac.38G>Ap.G13D16
20COSM48408GRB7lung,NS,carcinoma,adenocarcinomac.663G>Tp.Q221H16
21COSM48667PIK3C3lung,NS,carcinoma,adenocarcinomac.2096G>Cp.S699T16
22COSM44133TP53lung,NS,carcinoma,adenocarcinomac.859G>Tp.E287*16
23COSM6549TP53lung,NS,carcinoma,adenocarcinomac.743G>Tp.R248L16
24COSM517KRASlung,NS,carcinoma,adenocarcinomac.34G>Ap.G12S16
25COSM5369862ABL1lung,NS,carcinoma,adenocarcinomac.755A>Cp.Q252P16
26COSM48533MAP3K6lung,NS,carcinoma,adenocarcinomac.2011C>Gp.L671V16
27COSM28608EGFRlung,NS,carcinoma,adenocarcinomac.2393T>Ap.L798H16
28COSM94249ESR1lung,NS,carcinoma,adenocarcinomac.1470G>Cp.M490I16
29COSM96124PIK3CGlung,NS,carcinoma,adenocarcinomac.174G>Tp.L58L16
30COSM6241EGFRlung,NS,carcinoma,adenocarcinomac.2303G>Tp.S768I16
31COSM476BRAFlung,NS,carcinoma,adenocarcinomac.1799T>Ap.V600E16
32COSM95860EPHB3lung,NS,carcinoma,adenocarcinomac.2001G>Ap.L667L16
33COSM94072CELSR2lung,NS,carcinoma,adenocarcinomac.4028G>Cp.C1343S16
34COSM6239EGFRlung,NS,carcinoma,adenocarcinomac.2156G>Cp.G719A16
35COSM96225TBX22lung,NS,carcinoma,adenocarcinomac.1074C>Ap.P358P16
36COSM5679CTNNB1lung,NS,carcinoma,adenocarcinomac.110C>Gp.S37C16
37COSM43687TP53lung,NS,carcinoma,adenocarcinomac.641A>Gp.H214R16
38COSM44227TP53lung,NS,carcinoma,adenocarcinomac.854A>Tp.E285V16
39COSM94137DNERlung,NS,carcinoma,adenocarcinomac.863C>Tp.S288F16
40COSM48636PAK5lung,NS,carcinoma,adenocarcinomac.1190C>Ap.T397K16
41COSM95909FZD10lung,NS,carcinoma,adenocarcinomac.699C>Tp.I233I16
42COSM96261USP20lung,NS,carcinoma,adenocarcinomac.477C>Tp.A159A16
43COSM43615TP53lung,NS,carcinoma,adenocarcinomac.473G>Cp.R158P16
44COSM48578MYBlung,NS,carcinoma,adenocarcinomac.389G>Ap.C130Y16
45COSM48644PDGFRAlung,NS,carcinoma,adenocarcinomac.629C>Tp.A210V16
46COSM48461KDRlung,NS,carcinoma,adenocarcinomac.3434G>Ap.G1145E16
47COSM12374EGFRlung,NS,carcinoma,adenocarcinomac.2582T>Gp.L861R16
48COSM554KRASlung,NS,carcinoma,adenocarcinomac.183A>Cp.Q61H16
49COSM132957NFE2L2lung,NS,carcinoma,adenocarcinomac.242G>Ap.G81D16
50COSM48731RAP2Blung,NS,carcinoma,adenocarcinomac.38G>Tp.G13V16

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

6 (show top 50)    (show all 580)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
113394112300000GainLung adenocarcinoma
213409112300000GainLung adenocarcinoma
3139701102000000107000000LossLung adenocarcinoma
4139861102200000107200000LossLung adenocarcinoma
5145281109314358109386258DeletionWDR47Lung adenocarcinoma
6153841115048600115061038Copy numberNRASLung adenocarcinoma
7175601143480000149410000AmplificationARNTLung adenocarcinoma
8181431144218994144222801AmplificationRBM8ALung adenocarcinoma
9181611144227739144235088AmplificationPEX11BLung adenocarcinoma
10181761144287344144297903AmplificationPIAS3Lung adenocarcinoma
11182231144475951145932379AmplificationGPR89ALung adenocarcinoma
12183851145180914145234067AmplificationCHD1LLung adenocarcinoma
13184051145479805145564639AmplificationBCL9Lung adenocarcinoma
14184331145585791145609258AmplificationACP6Lung adenocarcinoma
15190031148137824148138969AmplificationBOLA1Lung adenocarcinoma
16190391148305965148384129AmplificationVPS45Lung adenocarcinoma
17191521148885329148936257AmplificationGOLPH3LLung adenocarcinoma
18191991149165511149203837AmplificationSETDB1Lung adenocarcinoma
19192071149221122149234738AmplificationANXA9Lung adenocarcinoma
20192141149247596149274813AmplificationPRUNELung adenocarcinoma
21192801149399337149404960AmplificationLYSMD1Lung adenocarcinoma
22192871149415557149429264AmplificationVPS72Lung adenocarcinoma
23192991149493820149506578AmplificationPSMD4Lung adenocarcinoma
24193411149638664149641036AmplificationPSMB4Lung adenocarcinoma
25193751149998746150002664AmplificationMRPL9Lung adenocarcinoma
26193781150009206150029634AmplificationTDRKHLung adenocarcinoma
27194321150271605150276135AmplificationS100A11Lung adenocarcinoma
28200471152787674152797744AmplificationUBE2Q1Lung adenocarcinoma
29200521152821157152867061AmplificationADARLung adenocarcinoma
30205691153196125153200882AmplificationPYGO2Lung adenocarcinoma
31205711153201397153213464AmplificationSHC1Lung adenocarcinoma
32205911153213790153218346AmplificationCKS1BLung adenocarcinoma
33205921153222440153232211AmplificationFLAD1Lung adenocarcinoma
34206171153302836153308653AmplificationEFNA4Lung adenocarcinoma
35206221153317971153326638AmplificationEFNA3Lung adenocarcinoma
36208381154761820154809020AmplificationIQGAP3Lung adenocarcinoma
37208531154828181154830715AmplificationAPOA1BPLung adenocarcinoma
38208631154936029154941999AmplificationCRABP2Lung adenocarcinoma
39208681154959036154964835AmplificationISG20L2Lung adenocarcinoma
40208721154973717154977547AmplificationMRPL24Lung adenocarcinoma
41208751154978522155003341AmplificationHDGFLung adenocarcinoma
42209831155749790155788934AmplificationFCRL5Lung adenocarcinoma
43210471156490550156494682AmplificationCD1ALung adenocarcinoma
44213351158163454158182010AmplificationIGSF9Lung adenocarcinoma
45213641158264085158268407AmplificationPIGMLung adenocarcinoma
46214221158525000158579978AmplificationCOPALung adenocarcinoma
47215161159308119159325966AmplificationPVRL4Lung adenocarcinoma
48215221159336969159354490AmplificationPFDN2Lung adenocarcinoma
49215271159354514159361857AmplificationNIT1Lung adenocarcinoma
50215331159390157159395270AmplificationUFC1Lung adenocarcinoma

Expression for genes affiliated with Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1TNNC1troponin C type 1 (slow)Lung-5.280.000
2COL11A1collagen, type XI, alpha 1Lung+5.070.000
3MMP1matrix metallopeptidase 1Lung+4.750.000
4AGERadvanced glycosylation end product-specific receptorLung-4.690.000
5WIF1WNT inhibitory factor 1Lung-4.600.000
6SOSTDC1sclerostin domain containing 1Lung-4.470.000
7FABP4fatty acid binding protein 4, adipocyteLung-4.320.000
8CDH3cadherin 3, type 1, P-cadherin (placental)Lung+4.310.000
9FOSBFBJ murine osteosarcoma viral oncogene homolog BLung-4.240.000
10TMEM100transmembrane protein 100Lung-4.200.000
11CLEC3BC-type lectin domain family 3, member BLung-4.180.000
12FCN3ficolin (collagen/fibrinogen domain containing) 3Lung-4.170.000
13MT1Mmetallothionein 1MLung-4.070.000
14SPP1secreted phosphoprotein 1Lung+4.040.000
15SPINK1serine peptidase inhibitor, Kazal type 1Lung+3.960.000
16COL10A1collagen, type X, alpha 1Lung+3.790.000
17CLIC5chloride intracellular channel 5Lung-3.650.000
18ADIRFadipogenesis regulatory factorLung-3.650.000
19RAMP2receptor (G protein-coupled) activity modifying protein 2Lung-3.620.000
20HIGD1BHIG1 hypoxia inducible domain family, member 1BLung-3.600.000
21STXBP6syntaxin binding protein 6 (amisyn)Lung-3.590.000
22TMPRSS4transmembrane protease, serine 4Lung+3.530.000
23EFCC1EF-hand and coiled-coil domain containing 1Lung-3.470.000
24MFAP4microfibrillar-associated protein 4Lung-3.470.000
25ABCC3ATP-binding cassette, sub-family C (CFTR/MRP), member 3Lung+3.470.000
26TOP2Atopoisomerase (DNA) II alphaLung+3.410.000
27TCF21transcription factor 21Lung-3.380.000
28CA4carbonic anhydrase IVLung-3.380.000
29CYP4B1cytochrome P450, family 4, subfamily B, polypeptide 1Lung-3.330.000
30GPM6Aglycoprotein M6ALung-3.300.000
31GINS2GINS complex subunit 2 (Psf2 homolog)Lung+3.290.000
32NEK2NIMA-related kinase 2Lung+3.270.000
33TOX3TOX high mobility group box family member 3Lung+3.240.000
34IL1RL1interleukin 1 receptor-like 1Lung-3.210.000
35PKNOX2PBX/knotted 1 homeobox 2Lung-3.210.000
36ABCA8ATP-binding cassette, sub-family A (ABC1), member 8Lung-3.170.000
37SCGB1A1secretoglobin, family 1A, member 1 (uteroglobin)Lung-3.170.000
38FIGFc-fos induced growth factor (vascular endothelial growth factor D)Lung-3.140.000
39CRABP2cellular retinoic acid binding protein 2Lung+3.110.000
40SGCGsarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)Lung-3.100.000
41ADAMTS8ADAM metallopeptidase with thrombospondin type 1 motif, 8Lung-3.080.000
42SFTPDsurfactant protein DLung-3.070.000
43MARCOmacrophage receptor with collagenous structureLung-3.070.000
44COL1A1collagen, type I, alpha 1Lung+3.050.000
45NMUneuromedin ULung+3.050.000

Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for genes affiliated with Lung Cancer Susceptibility 3

About this section

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50)    (show all 64)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.1EGFR, HRAS, KRAS
210.0HRAS, KRAS, TP53
310.0CASP3, EGFR, HRAS
4
Show member pathways
10.0CASP3, HRAS, KRAS
510.0EGFR, KRAS, RASSF1
610.0ERBB2, HRAS, TP53
710.0CDH1, EGFR, ERBB2
810.0CASP3, ERBB2, TP53
910.0EGFR, MMP2, TP53
1010.0CASP3, EGFR, MMP2
119.9CASP3, TP53, VEGFA
129.9CASP3, HRAS, MMP2
139.9EGFR, HRAS, KRAS, TP53
149.9EGFR, HRAS, KRAS, TP53
15
Show member pathways
9.9EGFR, HRAS, KRAS, STK11
16
Show member pathways
9.9EGFR, ERBB2, HRAS, KRAS
179.9EGFR, ERBB2, HRAS, KRAS
18
Show member pathways
9.9EGFR, ERBB2, HRAS, KRAS
19
Show member pathways
9.9EGFR, ERBB2, HRAS, KRAS
209.9EGFR, ERBB2, HRAS, KRAS
21
Show member pathways
9.9EGFR, ERBB2, HRAS, KRAS
229.9EGFR, ERBB2, HRAS, KRAS
23
Show member pathways
9.9HRAS, KRAS, STK11, TP53
249.9ERBB2, HRAS, KRAS, TP53
25
Show member pathways
9.9CASP3, HRAS, KRAS, TP53
269.9CASP3, HRAS, KRAS, TP53
27
Show member pathways
9.9EGFR, HRAS, KRAS, VEGFA
28
Show member pathways
9.9EGFR, HRAS, KRAS, VEGFA
299.9EGFR, HRAS, KRAS, VEGFA
309.9CDH1, HRAS, KRAS, TP53
319.8CDH1, EGFR, ERBB2, HRAS
32
Show member pathways
9.8EGFR, ERBB2, HRAS, MMP2
339.8CASP3, EGFR, HRAS, MMP2
34
Show member pathways
9.7EGFR, ERBB2, HRAS, KRAS, TP53
35
Show member pathways
9.7EGFR, ERBB2, HRAS, KRAS, TP53
369.7EGFR, ERBB2, HRAS, KRAS, TP53
37
Show member pathways
9.7CASP3, EGFR, HRAS, KRAS, TP53
389.7CASP3, EGFR, HRAS, KRAS, TP53
39
Show member pathways
9.7CASP3, EGFR, HRAS, KRAS, TP53
40
Show member pathways
9.7CASP3, EGFR, ERBB2, KRAS, TP53
41
Show member pathways
9.7CASP3, HRAS, KRAS, TP53, VEGFA
429.6CASP3, HRAS, KRAS, MMP2, VEGFA
43
Show member pathways
9.6EGFR, ERBB2, HRAS, KRAS, STK11, TP53
44
Show member pathways
9.6CASP3, EGFR, ERBB2, HRAS, KRAS, TP53
459.6CDH1, CEACAM5, MMP2, MSLN
469.5EGFR, HRAS, KRAS, STK11, TP53, VEGFA
47
Show member pathways
9.5EGFR, ERBB2, HRAS, KRAS, TP53, VEGFA
48
Show member pathways
9.5EGFR, ERBB2, HRAS, KRAS, MMP2, TP53
49
Show member pathways
9.5CDH1, EGFR, HRAS, KRAS, RASSF1, VEGFA
50
Show member pathways
9.5CASP3, CDH1, HRAS, KRAS, TP53, VEGFA

GO Terms for genes affiliated with Lung Cancer Susceptibility 3

About this section

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1cerebral cortex cell migrationGO:002179510.9EGFR, NKX2-1
2epidermal growth factor receptor signaling pathwayGO:000717310.8EGFR, HRAS, KRAS
3ERBB2 signaling pathwayGO:003812810.6EGFR, ERBB2, HRAS, KRAS
4cell cycle arrestGO:000705010.5HRAS, RASSF1, STK11, TP53
5positive regulation of epithelial cell proliferationGO:005067910.5EGFR, ERBB2, HRAS, VEGFA
6response to isolation stressGO:003590010.4HRAS, KRAS
7positive regulation of MAP kinase activityGO:004340610.3EGFR, ERBB2, HRAS, KRAS, VEGFA
8positive regulation of protein phosphorylationGO:000193410.2EGFR, ERBB2, HRAS, KRAS, VEGFA
9Ras protein signal transductionGO:000726510.2HRAS, KRAS, RASSF1, TP53
10positive regulation of gene expressionGO:001062810.1ERBB2, HRAS, KRAS, NKX2-1, TP53, VEGFA
11surfactant homeostasisGO:004312910.1NAPSA, VEGFA
12negative regulation of apoptotic processGO:004306610.0CASP3, CEACAM5, EGFR, OGG1, TP53, VEGFA

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1LRR domain bindingGO:003027510.7KRAS, STK11
2protein phosphatase bindingGO:001990310.2EGFR, ERBB2, TP53
3signal transducer, downstream of receptor, with protein tyrosine kinase activityGO:000471610.2EGFR, ERBB2

Sources for Lung Cancer Susceptibility 3

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet